Ticker

Analyst Price Targets — ANL

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
May 28, 2026 10:40 amOppenheimer$32.00$11.00TheFly Adlai Nortye initiated with an Outperform at Oppenheimer
April 20, 2026 10:10 amJoseph PantginisH.C. Wainwright$20.00$16.01TheFly Adlai Nortye price target raised to $20 from $16 at H.C. Wainwright
February 13, 2026 2:40 pmH.C. Wainwright$16.00$9.65TheFly Adlai Nortye upgraded to Buy at H.C. Wainwright as AN9025 enters clinic
September 4, 2024 6:04 amJoseph PantginisH.C. Wainwright$9.00$2.71TheFly Adlai Nortye initiated with a Buy at H.C. Wainwright

Latest News for ANL

Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025

First patient dosed in intermittent QW dosing arm with AN9025 Intermittent dosing offers a differentiated approach in the pan-RAS(ON) inhibitor space and may widen the therapeutic window based on preclinical data Both QD and QW arms are now enrolling SINGAPORE and NORTH BRUNSWICK, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd.

GlobeNewsWire • Jul 16, 2026
Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists

SINGAPORE and NORTH BRUNSWICK, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the expansion of its Scientific Advisory Board (SAB) with the appointments of two leading medical oncologists, Dr. David S. Hong and Dr. Piro Lito.

GlobeNewsWire • Jul 13, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for ANL.

No House trades found for ANL.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top